Sang Min Lee, Bum-Sup Jang, Won Park, Yong Bae Kim, Jin Ho Song, Jin Hee Kim, Tae Hyun Kim, In Ah Kim, Jong Hoon Lee, Sung-Ja Ahn, Kyubo Kim, Ah Ram Chang, Jeanny Kwon, Hae Jin Park, Kyung Hwan Shin
Cancer Res Treat. 2025;57(1):150-158. Published online July 12, 2024
Purpose This study aims to evaluate the treatment approaches and locoregional patterns for adenoid cystic carcinoma (ACC) in the breast, which is an uncommon malignant tumor with limited clinical data.
Materials and Methods A total of 93 patients diagnosed with primary ACC in the breast between 1992 and 2022 were collected from multi-institutions. All patients underwent surgical resection, including breast-conserving surgery (BCS) or total mastectomy (TM). Recurrence patterns and locoregional recurrence-free survival (LRFS) were assessed.
Results Seventy-five patients (80.7%) underwent BCS, and 71 of them (94.7%) received post-operative radiation therapy (PORT). Eighteen patients (19.3%) underwent TM, with five of them (27.8%) also receiving PORT. With a median follow-up of 50 months, the LRFS rate was 84.2% at 5 years. Local recurrence (LR) was observed in five patients (5.4%) and four cases (80%) of the LR occurred in the tumor bed. Three of LR (3/75, 4.0%) had a history of BCS and PORT, meanwhile, two of LR (2/18, 11.1%) had a history of mastectomy. Regional recurrence occurred in two patients (2.2%), and both cases had a history of PORT with (n=1) and without (n=1) irradiation of the regional lymph nodes. Partial breast irradiation (p=0.35), BCS (p=0.96) and PORT in BCS group (p=0.33) had no significant association with LRFS.
Conclusion BCS followed by PORT was the predominant treatment approach for ACC of the breast and LR mostly occurred in the tumor bed. The findings of this study suggest that partial breast irradiation might be considered for PORT in primary breast ACC.
Jae Sik Kim, Kyubo Kim, Wonguen Jung, Kyung Hwan Shin, Seock-Ah Im, Hee-Jun Kim, Yong Bae Kim, Jee Suk Chang, Jee Hyun Kim, Doo Ho Choi, Yeon Hee Park, Dae Yong Kim, Tae Hyun Kim, Byung Ock Choi, Sea-Won Lee, Suzy Kim, Jeanny Kwon, Ki Mun Kang, Woong-Ki Chung, Kyung Su Kim, Ji Ho Nam, Won Sup Yoon, Jin Hee Kim, Jihye Cha, Yoon Kyeong Oh, In Ah Kim
Cancer Res Treat. 2022;54(4):1121-1129. Published online December 31, 2021
Purpose We aimed to investigate manifestations and patterns of care for patients with brain metastasis (BM) from breast cancer (BC) and compared their overall survival (OS) from 2005 through 2014 in Korea.
Materials and Methods We retrospectively reviewed 600 BC patients with BM diagnosed between 2005 and 2014. The median follow-up duration was 12.5 months. We categorized the patients into three groups according to the year when BM was initially diagnosed (group I [2005-2008], 98 patients; group II [2009-2011], 200 patients; and group III [2012-2014], 302 patients).
Results Over time, the median age at BM diagnosis increased by 2.2 years (group I, 49.0 years; group II, 48.3 years; and group III, 51.2 years; p=0.008). The percentage of patients with extracranial metastasis was 73.5%, 83.5%, and 86.4% for group I, II, and III, respectively (p=0.011). The time interval between BC and BM was prolonged in patients with stage III primary BC (median, 2.4 to 3 years; p=0.029). As an initial brain-directed treatment, whole-brain radiotherapy alone decreased from 80.0% in 2005 to 41.1% in 2014. Meanwhile, stereotactic radiosurgery or fractionated stereotactic radiotherapy alone increased from 13.3% to 34.7% during the same period (p=0.005). The median OS for group I, II, and III was 15.6, 17.9, and 15.0 months, respectively, with no statistical significance.
Conclusion The manifestations of BM from BC and the pattern of care have changed from 2005 to 2014 in Korea. However, the OS has remained relatively unchanged over the 10 years.
Citations
Citations to this article as recorded by
Comparison of initial and sequential salvage brain-directed treatment in patients with 1–4 vs. 5–10 brain metastases from breast cancer (KROG 16–12) Jae Sik Kim, Kyubo Kim, Wonguen Jung, Kyung Hwan Shin, Seock-Ah Im, Hee-Jun Kim, Yong Bae Kim, Jee Suk Chang, Jee Hyun Kim, Doo Ho Choi, Yeon Hee Park, Dae Yong Kim, Tae Hyun Kim, Byung Ock Choi, Sea-Won Lee, Suzy Kim, Jeanny Kwon, Ki Mun Kang, Woong-Ki C Breast Cancer Research and Treatment.2023; 200(1): 37. CrossRef
Kyubo Kim, Jinhong Jung, Haeyoung Kim, Wonguen Jung, Kyung Hwan Shin, Ji Hyun Chang, Su Ssan Kim, Won Park, Jee Suk Chang, Yong Bae Kim, Sung Ja Ahn, Ik Jae Lee, Jong Hoon Lee, Hae Jin Park, Jihye Cha, Juree Kim, Jin Hwa Choi, Taeryool Koo, Jeanny Kwon, Jin Hee Kim, Mi Young Kim, Shin-Hyung Park, Yeon-Joo Kim
Cancer Res Treat. 2022;54(2):497-504. Published online August 25, 2021
Purpose
To evaluate the role of postmastectomy radiation therapy (PMRT) in patients with node-negative breast cancer of 5cm or larger tumors undergoing mastectomy
Materials and Methods
Medical records of 274 patients from 18 institutions treated with mastectomy between January 2000 and December 2016 were retrospectively reviewed. Among these, 202 patients underwent PMRT, while 72 did not. Two hundred and forty-one patients (88.0%) received systemic chemotherapy, and 172 (62.8%) received hormonal therapy. Patients receiving PMRT were younger, more likely to have progesterone receptor-positive tumors, and received adjuvant chemotherapy more frequently compared with those without PMRT (p <0.001, 0.018, and <0.001, respectively). Other characteristics were not significantly different between the two groups.
Results
With a median follow-up of 95 months (range, 1-249), there were 9 locoregional recurrences, and 20 distant metastases. The 8-year locoregional recurrence-free survival rates were 98.0% with PMRT and 91.3% without PMRT (p=0.133), and the 8-year disease-free survival (DFS) rates were 91.8% with PMRT and 73.9% without PMRT (p=0.008). On multivariate analysis incorporating age, histologic grade, lymphovascular invasion, hormonal therapy, chemotherapy, and PMRT, the absence of lymphovascular invasion and the receipt of PMRT were associated with improved DFS (p=0.025 and 0.009, respectively).
Conclusion
Locoregional recurrence rate was very low in node-negative breast cancer of 5cm or larger tumors treated with mastectomy regardless of the receipt of PMRT. However, PMRT was significantly associated with improved DFS. Further investigation is needed to confirm these findings.
Citations
Citations to this article as recorded by
Outcomes with and without postmastectomy radiotherapy for pT3N0‐1M0 breast cancer: An institutional experience Xinxin Rao, Xuanyi Wang, Kairui Jin, Yilan Yang, Xu Zhao, Zhe Pan, Weiluo Lv, Zhen Zhang, Li Zhang, Xiaoli Yu, Xiaomao Guo Cancer Medicine.2024;[Epub] CrossRef
The effect of radiotherapy on patients with pathological stage IIB breast cancer after breast-conserving surgery or mastectomy: A cohort study Yi-Ying Pan, Tzu-Yu Lai, Cheng-Ying Shiau, Ling-Ming Tseng, I-Chun Lai, Yu-Ming Liu, Pin-I Huang Journal of the Chinese Medical Association.2024; 87(2): 202. CrossRef
Post-mastectomy radiation therapy after breast reconstruction: from historic dogmas to practical expert agreements based on a large literature review of surgical and radiation therapy considerations Yazid Belkacemi, Meena S. Moran, Burcu Celet Ozden, Yazan Masannat, Fady Geara, Mohamed Albashir, Nhu Hanh To, Kamel Debbi, Mahmoud El Tamer Critical Reviews in Oncology/Hematology.2024; 200: 104421. CrossRef
Impact of the 21-gene recurrence score testing on chemotherapy selection and clinical outcomes in T3N0 luminal breast cancer Ke Liu, Jia-Yi Li, Guan-Qiao Li, Zhen-Yu He, San-Gang Wu Expert Review of Anticancer Therapy.2024; 24(12): 1283. CrossRef
Post-Mastectomy Radiation Therapy: Applications and Advancements Jessica L. Thompson, Steven G. Allen, Cecilia Pesavento, Corey W. Speers, Jacqueline S. Jeruss Current Breast Cancer Reports.2022; 14(3): 75. CrossRef
Yeon Joo Kim, Yeon-Joo Kim, Yong Bae Kim, Ik Jae Lee, Jeanny Kwon, Kyubo Kim, Jihye Cha, Myungsoo Kim, In Young Jo, Jung Hoon Kim, Jaehyeon Park, Jin Hee Kim, Juree Kim, Kyung Hwan Shin, Su Ssan Kim
Cancer Res Treat. 2022;54(2):478-487. Published online July 12, 2021
Purpose This study aimed to investigate the impact of postoperative radiotherapy (PORT) in de novo metastatic breast cancer (dnMBC) patients undergoing planned primary tumor resection (PTR) and to identify the subgroup of patients who would most benefit from PORT.
Materials and Methods This study enrolled 426 patients with dnMBC administered PTR alone or with PORT. The primary and secondary outcomes were overall and progression-free survival (OS and PFS), respectively.
Results The median follow-up time was 53.7 months (range, 3.1 to 194.4). The 5-year OS and PFS rates were 73.2% and 32.0%, respectively. For OS, clinical T3/4 category, triple-negative breast cancer (TNBC), postoperative chemotherapy alone were significantly poor prognostic factors, and administration of PORT failed to show its significance. Regarding PFS, PORT was a favorable prognostic factor (hazard ratio, 0.64; 95% confidence interval, 0.50 to 0.82; p < 0.001), in addition to T1/2 category, ≤ 5 metastases, and non-TNBC. According to the multivariate analyses of OS in the PORT group, we divided the patients into three groups (group 1, T1/2 and non-TNBC [n=193]; group 2, T3/4 and non-TNBC [n=171]; and group 3, TNBC [n=49]), and evaluated the effect of PORT. Although PORT had no significance for OS in all subgroups, it was a significant factor for good prognosis regarding PFS in groups 1 and 2, not in group 3.
Conclusion PORT was associated with a significantly better PFS in patients with dnMBC who underwent PTR. Patients with clinical T1/2 category and non-TNBC benefited most from PORT, while those with TNBC showed little benefit.
Citations
Citations to this article as recorded by
Letter to the editor for the article“Tumor margin irregularity degree is an important preoperative predictor of adverse pathology for clinical T1/2 renal cell carcinoma and the construction of predictive model” Yaping Miao, Lexin Wang, Ping Chen, Jiaan Lu, Guanhu Yang, Hao Chi World Journal of Urology.2024;[Epub] CrossRef
The prognostic differences and the effect of postmastectomy radiotherapy between post‐chemotherapy ypT1‐2ypN1 and de novo pT1‐2N1 breast cancer Tian Yang, Xiaorong Zhong, Jun Wang, Zhongzheng Xiang, Yuanyuan Zeng, Siting Yu, Zelei Dai, Ningyue Xu, Ting Luo, Lei Liu Cancer Medicine.2023; 12(7): 8112. CrossRef
Impact of high dose radiotherapy for breast tumor in locoregionally uncontrolled stage IV breast cancer: a need for a risk-stratified approach Nalee Kim, Haeyoung Kim, Won Park, Won Kyung Cho, Tae Gyu Kim, Young-Hyuck Im, Jin Seok Ahn, Yeon Hee Park, Ji-Yeon Kim Radiation Oncology.2023;[Epub] CrossRef
Machine learning predicts the prognosis of breast cancer patients with initial bone metastases Chaofan Li, Mengjie Liu, Jia Li, Weiwei Wang, Cong Feng, Yifan Cai, Fei Wu, Xixi Zhao, Chong Du, Yinbin Zhang, Yusheng Wang, Shuqun Zhang, Jingkun Qu Frontiers in Public Health.2022;[Epub] CrossRef
Factors Influencing Prognosis in Patients with De Novo Stage IV Breast Cancer: A Systematic Review and Meta-Analysis Meilin Zhang, Zining Jin, Yingying Xu, Bo Chen, Jian Song, Muyao Li, Feng Jin, Ang Zheng SSRN Electronic Journal .2022;[Epub] CrossRef
Yu Jin Lim, Sea-Won Lee, Noorie Choi, Jeanny Kwon, Keun-Yong Eom, Eunyoung Kang, Eun-Kyu Kim, Jee Hyun Kim, Yu Jung Kim, Se Hyun Kim, So Yeon Park, In Ah Kim
Cancer Res Treat. 2018;50(4):1140-1148. Published online December 7, 2017
Purpose
This study aimed to identify predictors for distant metastatic behavior and build a related prognostic nomogram in breast cancer.
Materials and Methods
A total of 1,181 patients with non-metastatic breast cancer between 2003 and 2011 were analyzed. To predict the probability of distant metastasis, a nomogram was constructed based on prognostic factors identified using a Cox proportional hazards model.
Results
The 7-year overall survival and 5-year post-progression survival of locoregional versus distant recurrence groups were 67.6% versus 39.1% (p=0.027) and 54.2% versus 33.5% (p=0.043), respectively. Patients who developed distant metastasis showed early and late mortality risk peaks within 3 and after 5 years of follow-up, respectively, but a broad and low risk increment was observed in other patients with locoregional relapse. In multivariate analysis of distant metastasis-free interval, age (≥ 45 years vs. < 45 years), molecular subtypes (luminal A vs. luminal B, human epidermal growth receptor 2, and triple negative), T category (T1 vs. T2-3 and T4), and N category (N0 vs. N1 and N2-3) were independently associated (p < 0.05 for all). Regarding the significant factors, a well-validated nomogram was established (concordance index, 0.812). The risk score level of patients with initial brain failure was higher than those of non-brain sites (p=0.029).
Conclusion
The nomogram could be useful for predicting the individual probability of distant recurrence in breast cancer. In high-risk patients based on the risk scores, more aggressive systemic therapy and closer surveillance for metastatic failure should be considered.
Citations
Citations to this article as recorded by
Predicting Patterns of Distant Metastasis in Breast Cancer Patients following Local Regional Therapy Using Machine Learning Audrey Shiner, Alex Kiss, Khadijeh Saednia, Katarzyna J. Jerzak, Sonal Gandhi, Fang-I Lu, Urban Emmenegger, Lauren Fleshner, Andrew Lagree, Marie Angeli Alera, Mateusz Bielecki, Ethan Law, Brianna Law, Dylan Kam, Jonathan Klein, Christopher J. Pinard, Ale Genes.2023; 14(9): 1768. CrossRef
Nomograms for Predicting Specific Distant Metastatic Sites and Overall Survival of Breast Invasive Ductal Carcinoma Patients After Surgery: A Large Population-Based Study Yuqian Feng, Yiting Zhang, Yuying Xiang, Kaibo Guo, Huimin Jin, Shanming Ruan, Zhuoya Guan Frontiers in Surgery.2022;[Epub] CrossRef
Cost-effectiveness of postmastectomy hypofractionated radiation therapy vs conventional fractionated radiation therapy for high-risk breast cancer Jing Yang, Shu-Nan Qi, Hui Fang, Yong-Wen Song, Jing Jin, Yue-Ping Liu, Wei-Hu Wang, Yong Yang, Yu Tang, Hua Ren, Bo Chen, Ning-Ning Lu, Yuan Tang, Ning Li, Hao Jing, Shu-Lian Wang, Ye-Xiong Li The Breast.2021; 58: 72. CrossRef
Prediction of distant metastatic recurrence by tumor-infiltrating lymphocytes in hormone receptor-positive breast cancer Koji Takada, Shinichiro Kashiwagi, Yuka Asano, Wataru Goto, Rika Kouhashi, Akimichi Yabumoto, Sae Ishihara, Tamami Morisaki, Masatsune Shibutani, Hiroaki Tanaka, Kosei Hirakawa, Masaichi Ohira BMC Women's Health.2021;[Epub] CrossRef
Nomogram for the personalisation of radiotherapy treatments in breast cancer patients Inmaculada Beato Tortajada, Carlos Ferrer Albiach, Virginia Morillo Macias The Breast.2021; 60: 255. CrossRef
Prognostic Factors and Nomograms to Predict Overall and Cancer-Specific Survival for Children with Wilms’ Tumor Fucai Tang, Hanbin Zhang, Zechao Lu, Jiamin Wang, Chengwu He, Zhaohui He Disease Markers.2019; 2019: 1. CrossRef
Score for the Survival Probability in Metastasis Breast Cancer: A Nomogram-Based Risk Assessment Model Zhenchong Xiong, Guangzheng Deng, Xinjian Huang, Xing Li, Xinhua Xie, Jin Wang, Zeyu Shuang, Xi Wang Cancer Research and Treatment.2018; 50(4): 1260. CrossRef
Jeanny Kwon, Keun-Young Eom, Young Seok Kim, Won Park, Mison Chun, Jihae Lee, Yong Bae Kim, Won Sup Yoon, Jin Hee Kim, Jin Hwa Choi, Sei Kyung Chang, Bae Kwon Jeong, Seok Ho Lee, Jihye Cha
Cancer Res Treat. 2018;50(3):964-974. Published online October 24, 2017
Purpose
We aimed to assess prognostic value of metastatic pelvic lymph node (mPLN) in early-stage cervical cancer treated with radical surgery followed by postoperative chemoradiotherapy. Also, we sought to define a high-risk group using prognosticators for recurrence.
Materials and Methods
A multicenter retrospective study was conducted using the data from 13 Korean institutions from 2000 to 2010. A total of 249 IB-IIA patients with high-risk factors were included. We evaluated distant metastasis-free survival (DMFS) and disease-free survival (DFS) in relation to clinicopathologic factors including pNstage, number of mPLN, lymph node (LN)ratio (number of positive LN/number of harvested LN), and log odds of mPLNs (log(number of positive LN+0.5/number of negative LN+0.5)).
Results
In univariate analysis, histology (squamous cell carcinoma [SqCC] vs. others), lymphovascular invasion (LVI), number of mPLNs (≤ 3 vs. > 3), LN ratio (≤ 17% vs. > 17%), and log odds of mPLNs (≤ ‒0.58 vs. > ‒0.58) were significant prognosticators for DMFS and DFS. Resection margin involvement only affected DFS. No significant survival difference was observed between pN0 patients and patients with 1-3 mPLNs. Multivariate analysis revealed that mPLN > 3, LVI, and non-SqCC were unfavorable index for both DMFS (p < 0.001, p=0.020, and p=0.031, respectively) and DFS (p < 0.001, p=0.017, and p=0.001, respectively). A scoring system using these three factors predicts risk of recurrence with relatively high concordance index (DMFS, 0.69; DFS, 0.71).
Conclusion
mPLN > 3 in early-stage cervical cancer affects DMFS and DFS. A scoring system using mPLNs > 3, LVI, and non-SqCC could stratify risk groups of recurrence in surgically resected early-stage cervix cancer with high-risk factors.
Citations
Citations to this article as recorded by
Should all cervical cancer patients with positive lymph node receive definitive radiotherapy: a population-based comparative study Yang Wang, Xingyu Liu, Jing Liu, Liying Liu, Yue Ma Archives of Gynecology and Obstetrics.2025; 311(1): 123. CrossRef
Current Paradigm and Future Directions in the Management of Nodal Disease in Locally Advanced Cervical Cancer Elki Sze-Nga Cheung, Philip Yuguang Wu Cancers.2025; 17(2): 202. CrossRef
Spectral computed tomography in the assessment of metastatic lymph nodes in cervical cancer patients treated with definitive radiotherapy: a single-center, prospective study Zheng Zeng, Yining Chen, Yuliang Sun, Bing Zhou, Haoran Xu, Lei He, Ke Hu, Jie Qiu, Fuquan Zhang, Junfang Yan Clinical & Experimental Metastasis.2025;[Epub] CrossRef
Significance of tumor size and number of positive nodes in patients with FIGO 2018 stage IIIC1 cervical cancer Michihide Maeda, Seiji Mabuchi, Mina Sakata, Satoki Deguchi, Reisa Kakubari, Shinya Matsuzaki, Tsuyoshi Hisa, Shoji Kamiura Japanese Journal of Clinical Oncology.2024; 54(2): 146. CrossRef
Internal Validation of Predictive Models for Recurrence-Free Survival and Risk of Recurrence in Patients with Figo Stages I–IV Cervical Cancer Jorge Cea García, Francisco Márquez Maraver, M. Carmen Rubio Rodríguez, Laura Ríos-Pena, Inmaculada Rodríguez Jiménez Indian Journal of Gynecologic Oncology.2024;[Epub] CrossRef
Prediction of recurrence-related factors for patients with early-stage cervical cancer following radical hysterectomy and adjuvant radiotherapy Gui-Fen Ma, Gen-Lai Lin, Si-Tong Wang, Ya-Yu Huang, Chun-Li Xiao, Jing Sun, Ting-Yan Shi, Li-Bing Xiang BMC Women's Health.2024;[Epub] CrossRef
Based on 3D-PDU and clinical characteristics nomogram for prediction of lymph node metastasis and lymph-vascular space invasion of early cervical cancer preoperatively Shuang Dong, Yan-Qing Peng, Ya-Nan Feng, Xiao-Ying Li, Li-Ping Gong, Shuang Zhang, Xiao-Shan Du, Li-Tao Sun BMC Women's Health.2024;[Epub] CrossRef
Predictive value of number of metastatic lymph nodes and lymph node ratio for prognosis of patients with FIGO 2018 stage IIICp cervical cancer: a multi-center retrospective study Yanna Ye, Rui Lian, Zhiqiang Li, Xiaolin Chen, Yahong Huang, Jilong Yao, Anwei Lu, Jinghe Lang, Ping Liu, Chunlin Chen BMC Cancer.2024;[Epub] CrossRef
Prognostic Factors for Cervical Cancer in Asian Populations: A Scoping Review of Research From 2013 to 2023 Syed S Abrar, Seoparjoo Azmel Mohd Isa, Suhaily Mohd Hairon, Najib M Yaacob, Mohd Pazudin Ismail Cureus.2024;[Epub] CrossRef
New Classification of Tumor Microvessels and the Risk of Regional Metastasis in Squamous Cell and Glandular Cancers
Marina Senchukova American Journal of Clinical and Experimental Medicine.2024; 12(5): 61. CrossRef
Analysis of prognostic factors for cervical mucinous adenocarcinoma and establishment and validation a nomogram: a SEER-based study Yiping Hao, Qingqing Liu, Ruowen Li, Zhonghao Mao, Nan Jiang, Bingyu Wang, Wenjing Zhang, Baoxia Cui Journal of Obstetrics and Gynaecology.2023;[Epub] CrossRef
Validation of the 2018 FIGO Staging System for Predicting the Prognosis of Patients With Stage IIIC Cervical Cancer Xingtao Long, Misi He, Lingling Yang, Dongling Zou, Dong Wang, Yuemei Chen, Qi Zhou Clinical Medicine Insights: Oncology.2023;[Epub] CrossRef
Development of novel tracers for sentinel node identification in cervical cancer Keisuke Kodama, Chuya Tateishi, Tsuyoshi Oda, Lin Cui, Kazutaka Kuramoto, Hideaki Yahata, Kaoru Okugawa, Shoji Maenohara, Hiroshi Yagi, Masafumi Yasunaga, Ichiro Onoyama, Kazuo Asanoma, Takeshi Mori, Yoshiki Katayama, Kiyoko Kato Cancer Science.2023; 114(11): 4216. CrossRef
Preoperative prediction of cervical cancer survival using a high-resolution MRI-based radiomics nomogram Jia Li, Hao Zhou, Xiaofei Lu, Yiren Wang, Haowen Pang, Daniel Cesar, Aiai Liu, Ping Zhou BMC Medical Imaging.2023;[Epub] CrossRef
Abdominal Radical Hysterectomy as an Alternative Treatment Option for Patients with Cervical Cancer without Access to Radiotherapy Facilities Yanna Ye, Zhiqiang Li, Biliang Chen, Shan Kang, Bin Ling, Li Wang, Jilong Yao, Jinghe Lan, Ping Liu, Chunlin Chen Clinical and Experimental Obstetrics & Gynecology.2023;[Epub] CrossRef
Canine anal sac gland carcinoma with regional lymph node metastases treated with sacculectomy and lymphadenectomy: Outcome and possible prognostic factors Jean‐Benoit Tanis, Angharad B. Simlett‐Moss, Malgorzata Ossowksa, Thomas W. Maddox, James Guillem, Cristobal Lopez‐Jimenez, Gerry Polton, Rachel Burrow, Riccardo Finotello Veterinary and Comparative Oncology.2022; 20(1): 276. CrossRef
The prognostic value of the number of positive lymph nodes and the lymph node ratio in early‐stage cervical cancer Ester P. Olthof, Constantijne H. Mom, Malou L. H. Snijders, Hans H. B. Wenzel, Jacobus van der Velden, Maaike A. van der Aa Acta Obstetricia et Gynecologica Scandinavica.2022; 101(5): 550. CrossRef
Development and Validation of Novel Nomograms to Predict the Overall Survival and Cancer-Specific Survival of Cervical Cancer Patients With Lymph Node Metastasis Jianying Yi, Zhili Liu, Lu Wang, Xingxin Zhang, Lili Pi, Chunlei Zhou, Hong Mu Frontiers in Oncology.2022;[Epub] CrossRef
Treatment Strategies and Prognostic Factors of 2018 FIGO Stage IIIC Cervical Cancer: A Review Fengying Qin, Huiting Pang, Tao Yu, Yahong Luo, Yue Dong Technology in Cancer Research & Treatment.2022;[Epub] CrossRef
Tumoral Morphologic Features From Cervical Biopsies That Are Predictive of a Negligible Risk for Nodal Metastasis and Tumor Recurrence in Usual-type Cervical Adenocarcinomas Yue Wang, Ruby Jean Chang, Rong-Zhen Luo, Jing Yu, Xiaofei Zhang, Xianghong Yang, M.R. Quddus, Li Li, Wentao Yang, Aijun Liu, Qingping Jiang, Ruijiao Zhao, Huiting Zhu, Feng Zhou, Yiying Wang, Xiujie Sheng, Li-Li Liu, Yan-Lin Wen, Natalie Banet, C.J. Sung American Journal of Surgical Pathology.2022; 46(5): 713. CrossRef
Significance of the Number and the Location of Metastatic Lymph Nodes in Locally Recurrent or Persistent Cervical Cancer Patients Treated with Salvage Hysterectomy plus Lymphadenectomy Seiji Mabuchi, Naoko Komura, Michiko Kodama, Michihide Maeda, Yuri Matsumoto, Shoji Kamiura Current Oncology.2022; 29(7): 4856. CrossRef
Development and validation of a nomogram for predicting pelvic lymph node metastasis and prognosis in patients with cervical cancer Mengting Wang, Min Ma, Liju Yang, Chengtong Liang Frontiers in Oncology.2022;[Epub] CrossRef
High expression of PYK2 is associated with poor prognosis and cancer progression in early-stage cervical carcinoma Can Zhang, Xinghua Zhu, Yong Li, Jia Shao, Haibo Xu, Lei Chen, Youli Dan, Hua Jin, Aiqin He Medicine.2022; 101(41): e31178. CrossRef
Whether individualized dose escalation should be recommended for lymph nodes with different sizes in the definitive radiotherapy of cervical cancer? Xiaojuan Lv, Huiting Rao, Tao Feng, Chufan Wu, Hanmei Lou Radiation Oncology.2022;[Epub] CrossRef
Prognostic value of lymph node ratio in cervical cancer: A meta-analysis Haixia Cui, Yuan Huang, Weibo Wen, Xiangdan Li, Dongyuan Xu, Lan Liu Medicine.2022; 101(42): e30745. CrossRef
The Impact of Revised FIGO 2018 Staging System on Survival Outcomes in Patients with Carcinoma Cervix Sharanya Sathish, Geeta Acharaya, Kiran Kulkarni, Gayatri Ravikumar Indian Journal of Gynecologic Oncology.2022;[Epub] CrossRef
Lymph Node Ratio Is a Strong Prognostic Factor in Patients with Early-Stage Cervical Cancer Undergoing Minimally Invasive Radical Hysterectomy Se Ik Kim, Tae Hun Kim, Maria Lee, Hee Seung Kim, Hyun Hoon Chung, Taek Sang Lee, Hye Won Jeon, Jae-Weon Kim, Noh Hyun Park, Yong-Sang Song Yonsei Medical Journal.2021; 62(3): 231. CrossRef
Recurrence pattern and prognostic factors for survival in cervical cancer with lymph node metastasis Cigdem Kilic, Gunsu Kimyon Comert, Caner Cakir, Dilek Yuksel, Bahadır Codal, Fatih Kilic, Osman Turkmen, Alper Karalok, Ozlem Moraloglu Tekin, Nurettin Boran, Taner Turan Journal of Obstetrics and Gynaecology Research.2021; 47(6): 2175. CrossRef
Risk factors for nodal failure after radiochemotherapy and image guided brachytherapy in locally advanced cervical cancer: An EMBRACE analysis Max Peters, Astrid A.C. de Leeuw, Christel N. Nomden, Kari Tanderup, Kathrin Kirchheiner, Jacob C. Lindegaard, Christian Kirisits, Christine Haie-Meder, Alina Sturdza, Lars Fokdal, Umesh Mahantshetty, Peter Hoskin, Barbara Segedin, Kjersti Bruheim, Bhavan Radiotherapy and Oncology.2021; 163: 150. CrossRef
Prognostic Value of Lymph Node Characteristics in Patients with Cervical Cancer Treated with Radical Hysterectomy Yoon Hee Lee, Gun Oh Chong, Su Jeong Kim, Ja Hyun Hwang, Jong Mi Kim, Nora Jee-Young Park, Dae Gy Hong Cancer Management and Research.2021; Volume 13: 8137. CrossRef
The Combination of T Stage and the Number of Pathologic Lymph Nodes Provides Better Prognostic Discrimination in Early-Stage Cervical Cancer With Lymph Node Involvement Yongrui Bai, Ling Rong, Bin Hu, Xiumei Ma, Jiahui Wang, Haiyan Chen Frontiers in Oncology.2021;[Epub] CrossRef
The prognostic value of lymph node ratio in stage IIIC cervical cancer patients triaged to primary treatment by radical hysterectomy with systematic pelvic and para-aortic lymphadenectomy Koray Aslan, Mehmet Mutlu Meydanli, Murat Oz, Yusuf Aytac Tohma, Ali Haberal, Ali Ayhan Journal of Gynecologic Oncology.2020;[Epub] CrossRef
Predictive value of preoperative serum squamous cell carcinoma antigen (SCC–Ag) level on tumor recurrence in cervical squamous cell carcinoma patients treated with radical surgery: A single-institution study Qinhao Guo, Jun Zhu, Yong Wu, Hao Wen, Lingfang Xia, Xiaohua Wu, Xingzhu Ju European Journal of Surgical Oncology.2020; 46(1): 131. CrossRef
Effects of preoperative radiotherapy or chemoradiotherapy on postoperative pathological outcome of cervical cancer——from the large database of 46,313 cases of cervical cancer in China Weili Li, Ping Liu, Weidong Zhao, Zhaohong Yin, Zhong Lin, Xiaonong Bin, Jinghe Lang, Chunlin Chen European Journal of Surgical Oncology.2020; 46(1): 148. CrossRef
DSG2 expression is correlated with poor prognosis and promotes early-stage cervical cancer Shuhang Qin, Yuandong Liao, Qiqiao Du, Wei Wang, Jiaming Huang, Pan Liu, Chunliang Shang, Tianyu Liu, Meng Xia, Shuzhong Yao Cancer Cell International.2020;[Epub] CrossRef
Should the Number of Metastatic Pelvic Lymph Nodes Be Integrated into the 2018 Figo Staging Classification of Early Stage Cervical Cancer? Luigi Pedone Anchora, Vittoria Carbone, Valerio Gallotta, Francesco Fanfani, Francesco Cosentino, Luigi Carlo Turco, Camilla Fedele, Nicolò Bizzarri, Giovanni Scambia, Gabriella Ferrandina Cancers.2020; 12(6): 1552. CrossRef
UGT1A1 polymorphism has a prognostic effect in patients with stage IB or II uterine cervical cancer and one or no metastatic pelvic nodes receiving irinotecan chemotherapy: a retrospective study Hideki Matsuoka, Ryusuke Murakami, Kaoru Abiko, Ken Yamaguchi, Akihito Horie, Junzo Hamanishi, Tsukasa Baba, Masaki Mandai BMC Cancer.2020;[Epub] CrossRef
Validation of the 2018 FIGO Classification for Cervical Cancer: Lymphovascular Space Invasion Should Be Considered in IB1 Stage Vincent Balaya, Benedetta Guani, Laurent Magaud, Hélène Bonsang-Kitzis, Charlotte Ngô, Patrice Mathevet, Fabrice Lécuru Cancers.2020; 12(12): 3554. CrossRef
Burden of lymphatic disease predicts efficacy of adjuvant radiation and chemotherapy in FIGO 2018 stage IIICp cervical cancer Giorgio Bogani, Daniele Vinti, Ferdinando Murgia, Valentina Chiappa, Umberto Leone Roberti Maggiore, Fabio Martinelli, Antonino Ditto, Francesco Raspagliesi International Journal of Gynecological Cancer.2019; 29(9): 1355. CrossRef
Prognostic factors for and pattern of lymph-node involvement in patients with operable cervical cancer P. Widschwendter, W. Janni, C. Scholz, A. De Gregorio, N. De Gregorio, T W P Friedl Archives of Gynecology and Obstetrics.2019; 300(6): 1709. CrossRef
Postoperative chemotherapy for node-positive cervical cancer: Results of a multicenter phase II trial (JGOG1067) Maki Matoda, Nobuhiro Takeshima, Hirofumi Michimae, Takashi Iwata, Harushige Yokota, Yutaka Torii, Yorito Yamamoto, Kazuhiro Takehara, Shin Nishio, Hirokuni Takano, Mika Mizuno, Yoshiyuki Takahashi, Yuji Takei, Tetsuya Hasegawa, Mikio Mikami, Takayuki Eno Gynecologic Oncology.2018; 149(3): 513. CrossRef
Purpose
Few studies for occult breast cancer (OBC) have evaluated the effect of radiotherapy (RT) after mastectomy or axillary lymph node dissection (ALND) with/without breast surgery. Therefore, we investigated clinicopathologic factors of OBC with the impact of postoperative RT to determine its prognostic significance using large population-based data.
Materials and Methods
We performed a retrospective cohort study using the Surveillance, Epidemiology, and End Results (SEER) database from 1983 to 2013. A total of 1,045 eligible patients with OBC were identified. We compared overall survival (OS) using Cox proportional hazards regression with propensity score matching after verifying an imbalance of prognosticators between RT group (n=518) and non-RT group (n=479).
Results
Patients with age < 70 (p=0.033), married marital status (p < 0.001), undergoing ALND (p < 0.001), more examined lymph nodes (LNs) (p < 0.001), and more metastatic LNs (p < 0.001) were more likely to receive RT. Multivariate analysis after propensity score matching (n=798) showed that patients treated with RT survived significantly longer than those without RT (5-year OS, 81.5% vs. 78.3%; p=0.014). A significantly prolonged OS was observed when RT was given to patients treated with mastectomy (p=0.033), those treated with ALND (p=0.036), or those with more than seven metastatic LNs (p=0.016).
Conclusion
RT may offer survival benefit in OBC even after mastectomy or ALND, especially in patients with more than seven metastatic LNs. Further prospective studies are needed to validate these findings.
Citations
Citations to this article as recorded by
Occult breast cancer in an older woman: A case report Cong Liu, Hua Xing Experimental and Therapeutic Medicine.2024;[Epub] CrossRef
Reconceptualizing the clinicopathological features, locoregional therapy and prognostic factors of occult breast cancer in the era of molecular subtyping Xin Ye, Li Yang, Qi He, Xiaoyan Lin, Jie Wang, Rongrong Cui, Cheng Xu Women & Health.2023; 63(2): 105. CrossRef
Prognostic Models Using Machine Learning Algorithms and Treatment Outcomes of Occult Breast Cancer Patients Jingkun Qu, Chaofan Li, Mengjie Liu, Yusheng Wang, Zeyao Feng, Jia Li, Weiwei Wang, Fei Wu, Shuqun Zhang, Xixi Zhao Journal of Clinical Medicine.2023; 12(9): 3097. CrossRef
Best treatment options for occult breast cancer: A meta-analysis Rong Wang, Hong-xin Yang, Jie Chen, Jian-jun Huang, Qing Lv Frontiers in Oncology.2023;[Epub] CrossRef
Occult Breast Cancer Patients with Mastectomy have Better Prognosis than those with Breast-Conserving Therapy Jiayi Li, Gang Liu, Ziqi Jia, Fei Ren, Dawei Dong, Menglu Zhang, Xiang Wang, Yipeng Wang Future Oncology.2023; 19(36): 2405. CrossRef
Surgical treatment trends and identification of primary breast tumors after surgery in occult breast cancer: a study based on the Japanese National Clinical Database—Breast Cancer Registry Mitsuo Terada, Minoru Miyashita, Hiraku Kumamaru, Hiroaki Miyata, Kenji Tamura, Masayuki Yoshida, Etsuyo Ogo, Masayuki Nagahashi, Sota Asaga, Yasuyuki Kojima, Takayuki Kadoya, Kenjiro Aogi, Naoki Niikura, Kotaro Iijima, Naoki Hayashi, Makoto Kubo, Yutaka Breast Cancer.2022; 29(4): 698. CrossRef
Occult Breast Cancer Presented with Axillary Lymph Node Metastases: A Small Case Series to a Frustrating Medical Issue D. Mantas, Z. Garoufalia, C. Kontzoglou Indian Journal of Surgery.2021; 83(S2): 364. CrossRef
Treatment for occult breast cancer: A propensity score analysis of the National Cancer Database Catherine Tsai, Beiqun Zhao, Theresa Chan, Sarah L. Blair The American Journal of Surgery.2020; 220(1): 153. CrossRef
Outcome of breast-conserving treatment for axillary lymph node metastasis from occult breast cancer with negative breast MRI Haeyoung Kim, Won Park, Su Ssan Kim, Sung Ja Ahn, Yong Bae Kim, Tae Hyun Kim, Jin Hee Kim, Jin-Hwa Choi, Hae Jin Park, Jee Suk Chang, Doo Ho Choi The Breast.2020; 49: 63. CrossRef
Breast-Conserving Surgery in Patients With Mammary Paget's Disease Yufeng Yao, Li Sun, Yan Meng, Yan Zhuang, Lin Zhao, Qiao Yu, Chengshuai Si Journal of Surgical Research.2019; 241: 178. CrossRef
Evaluation of the benefit of post‑mastectomy radiotherapy in patients with early‑stage breast cancer: A propensity score matching study Wenjie Shi, Youhong Luo, Dongkang Zhao, Hao Huang, Weiyi Pang Oncology Letters.2019;[Epub] CrossRef
Purpose
While curative resection is the only chance of cure in pancreatic cancer, controversies exist about the impact of surgical margin status on survival. Non-standardized pathologic report and different criteria on the R1 status made it difficult to implicate adjuvant therapy after resection based on the margin status. We evaluated the influence of resection margins on survival by meta-analysis.
Materials and Methods
We thoroughly searched electronic databases of PubMed, EMBASE, and Cochrane Library. We included studies reporting survival outcomeswith different margin status: involved margin (R0 mm), margin clearance with ≤ 1 mm (R0-1 mm), and margin with > 1 mm (R>1 mm). Hazard ratio (HR) for overall survival was extracted, and a random-effects model was used for pooled analysis.
Results
A total of eight retrospective studies involving 1,932 patients were included. Pooled HR for overall survival showed that patients with R>1 mm had reduced risk of death than those with R0-1 mm (HR, 0.74; 95% confidence interval [CI], 0.61 to 0.88; p=0.001). In addition, patients with R0-1 mm had reduced risk of death than those with R0 mm (HR, 0.81; 95% CI, 0.72 to 0.91; p < 0.001). There was no heterogeneity between the included studies (I 2 index, 42% and 0%; p=0.10 and p=0.82, respectively).
Conclusion
Our results suggest that stratification of the patients based on margin status is warranted in the clinical trials assessing the role of adjuvant treatment for pancreatic cancer.
Citations
Citations to this article as recorded by
Clinical outcomes in borderline and locally advanced pancreatic cancer with the addition of low-dose-rate brachytherapy to standard of care therapy Ross J. Taylor, Gregory J. Matthews, Robert H. Aseltine, Emma C. Fields Brachytherapy.2024; 23(3): 355. CrossRef
Laparoscopic radical antegrade modular pancreatosplenectomy (RAMPS) for adenocarcinoma of the body and tail of the pancreas — technical considerations with analysis of surgical outcomes Maciej Borys, Michał Wysocki, Krystyna Gałązka, Maciej Stanek, Andrzej Budzyński Langenbeck's Archives of Surgery.2024;[Epub] CrossRef
Neoadjuvant treatment for pancreatic cancer: Controversies and advances Douglas Dias e Silva, Vincent Chung Cancer Treatment and Research Communications.2024; 39: 100804. CrossRef
Stapled Arterial Divestment in Surgery for Locally Advanced Pancreatic Cancer Krishna Kotecha, Juanita Chui, Kai Brown, Anubhav Mittal, Jaswinder Samra Journal of Surgical Oncology.2024;[Epub] CrossRef
Evaluation of local recurrence after pancreaticoduodenectomy for borderline resectable pancreatic head cancer with neoadjuvant chemotherapy: Can the resection level change after chemotherapy? Kosuke Kobayashi, Yoshihiro Ono, Shoki Sato, Tomotaka Kato, Atsushi Oba, Takafumi Sato, Hiromichi Ito, Yosuke Inoue, Manabu Takamatsu, Akio Saiura, Yu Takahashi Surgery.2023; 173(5): 1220. CrossRef
Rhabdoid carcinoma of the pancreas: A rare cause of unidentified carcinomas of the pancreas Ayoub Madani, Anass Derkaoui, Tarik Deflaoui, Hanane El Aggari, Nadir Miry, Benani Amal, Rachid Jabi, Mohamed Bouziane Surgery Open Digestive Advance.2023; 9: 100076. CrossRef
Prognostic significance of margin clearance in pancreaticoduodenectomy specimens with pancreatic ductal adenocarcinoma in a Danish population-based nationwide study Trine Aaquist, Claus W. Fristrup, Jane P. Hasselby, Stephen Hamilton-Dutoit, Mikkel Eld, Per Pfeiffer, Michael B. Mortensen, Sönke Detlefsen HPB.2023; 25(7): 826. CrossRef
Practice Patterns and Survival in Patients with Resected Pancreatic Ductal Adenocarcinomas (PDAC) — Results from the Multicentre Indian Pancreatic & Periampullary Adenocarcinoma Project (MIPPAP) Study Vikram Chaudhari, Anant Ramaswamy, Sujay Srinivas, Ajit Agarwal, Ramakrishnan Ayloor Seshadri, Vineet Talwar, Prabhat Bhargava, Shaifali Goel, Smita Kayal, Pradeep Rebala, Bharat Prajapati, Devendra Parikh, Jagdish Kothari, Ramesh M. Ch, Jacob Mathew Kada Journal of Gastrointestinal Cancer.2023; 54(4): 1338. CrossRef
Preoperative prediction of disease-free survival in pancreatic ductal adenocarcinoma patients after R0 resection using contrast-enhanced CT and CA19-9 Dengfeng Li, Qing Peng, Leyao Wang, Wei Cai, Meng Liang, Siyun Liu, Xiaohong Ma, Xinming Zhao European Radiology.2023; 34(1): 509. CrossRef
Predicting resection margin status of pancreatic neuroendocrine tumors on CT: performance of NCCN resectability criteria Dong Hwan Kim, Bohyun Kim, Dong Jin Chung, Kyung Ah Kim, Su Lim Lee, Moon Hyung Choi, Hokun Kim, Sung Eun Rha The British Journal of Radiology.2023;[Epub] CrossRef
Biliary Adverse Events during Neoadjuvant Therapy for Pancreatic Cancer Sam Z. Thalji, Deemantha Fernando, Kulwinder S. Dua, Srivats Madhavan, Phillip Chisholm, Zachary L. Smith, Mohammed Aldakkak, Kathleen K. Christians, Callisia N. Clarke, Ben George, Mandana Kamgar, Beth A. Erickson, William A. Hall, Douglas B. Evans, Susa Annals of Surgery.2023;[Epub] CrossRef
Lymph Node Stations of Pancreas Which Are Identified in Real Color Sectioned Images of a Cadaver With Pancreatic Cancer Chung Yoh Kim, Yongwook Jung, Jin Seo Park Journal of Korean Medical Science.2023;[Epub] CrossRef
CivaSheet intraoperative radiation therapy for pancreatic cancer Ross J. Taylor, Dorin Todor, Brian J. Kaplan, Weston Stover, Emma C. Fields Brachytherapy.2022; 21(2): 255. CrossRef
Four-Tier Pathologic Tumor Regression Grading System Predicts the Clinical Outcome in Patients Who Undergo Surgical Resection for Locally Advanced Pancreatic Cancer after Neoadjuvant Chemotherapy Soomin Ahn, Jong-chan Lee, Jaihwan Kim, Young Hoon Kim, Yoo-Seok Yoon, Ho-Seong Han, Haeryoung Kim, Jin-Hyeok Hwang Gut and Liver.2022; 16(1): 129. CrossRef
Preoperative Serum Carbohydrate Antigen 19-9 Levels Cannot Predict the Surgical Resectability of Pancreatic Cancer: A Meta-Analysis Márton Benke, Nelli Farkas, Péter Hegyi, Benedek Tinusz, Patrícia Sarlós, Bálint Erőss, Kata Szemes, Nóra Vörhendi, Zsolt Szakács, Ákos Szücs Pathology and Oncology Research.2022;[Epub] CrossRef
Neoadjuvant therapy in pancreatic ductal adenocarcinoma: A competing risk analysis Carlo Alberto Pacilio, Elisa Grassi, Andrea Gardini, Francesca Fappiano, Alessandro Passardi, Giovanni Luca Frassineti, Stefano Tamberi, Giorgio Ercolani Surgical Practice.2022; 26(3): 155. CrossRef
Prediction of tumour grade and survival outcome using pre-treatment PET- and MRI-derived imaging features in patients with resectable pancreatic ductal adenocarcinoma Vincent Dunet, Nermin Halkic, Christine Sempoux, Nicolas Demartines, Michael Montemurro, John O. Prior, Sabine Schmidt European Radiology.2021; 31(2): 992. CrossRef
First report on the feasibility of a permanently implantable uni-directional planar low dose rate brachytherapy sheet for patients with resectable or borderline resectable pancreatic cancer Joshua B. Dault, Dorin Todor, Brian J. Kaplan, Jennifer L. Myers, Emma C. Fields Brachytherapy.2021; 20(1): 207. CrossRef
Periarterial divestment in pancreatic cancer surgery Markus K. Diener, André L. Mihaljevic, Oliver Strobel, Martin Loos, Thomas Schmidt, Martin Schneider, Christoph Berchtold, Arianeb Mehrabi, Beat P. Müller-Stich, Kuirong Jiang, John P. Neoptolemos, Thilo Hackert, Yi Miao, Markus W. Büchler Surgery.2021; 169(5): 1019. CrossRef
Advances and challenges of neoadjuvant therapy in pancreatic cancer Yang Yu, Peng Zheng, Yajing Chen, Bofang Wang, Maswikiti Ewetse Paul, Pengxian Tao, Dengfeng Wang, Haiyuan Li, Baohong Gu, Lei Gao, Dan Wang, Hao Chen Asia-Pacific Journal of Clinical Oncology.2021; 17(6): 425. CrossRef
R Status is a Relevant Prognostic Factor for Recurrence and Survival After Pancreatic Head Resection for Ductal Adenocarcinoma Stefano Crippa, Fabio Giannone, Marco Schiavo Lena, Giulio Belfiori, Stefano Partelli, Domenico Tamburrino, Roberto Delpini, Michele Pagnanelli, Nicolo Pecorelli, Gianpaolo Balzano, Claudio Doglioni, Massimo Falconi Annals of Surgical Oncology.2021; 28(8): 4602. CrossRef
Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy Ryan K. Schmocker, Daniel Delitto, Michael J. Wright, Ding Ding, John L. Cameron, Kelly J. Lafaro, William R. Burns, Christopher L. Wolfgang, Richard A. Burkhart, Jin He Journal of the American College of Surgeons.2021; 232(4): 405. CrossRef
A Novel DNA Replication-Related Signature Predicting Recurrence After R0 Resection of Pancreatic Ductal Adenocarcinoma: Prognostic Value and Clinical Implications Zengyu Feng, Kexian Li, Jianyao Lou, Mindi Ma, Yulian Wu, Chenghong Peng Frontiers in Cell and Developmental Biology.2021;[Epub] CrossRef
Impact of resection margin status on survival in advanced N stage pancreatic cancer – a multi-institutional analysis Christian Teske, Richard Stimpel, Marius Distler, Susanne Merkel, Robert Grützmann, Louisa Bolm, Ulrich Wellner, Tobias Keck, Daniela E. Aust, Jürgen Weitz, Thilo Welsch Langenbeck's Archives of Surgery.2021; 406(5): 1481. CrossRef
Radical antegrade modular pancreatosplenectomy (RAMPS) versus conventional distal pancreatectomy for left-sided pancreatic cancer: findings of a multicenter, retrospective, propensity score matching study Hyung Sun Kim, Tae Ho Hong, Young-Kyoung You, Joon Seong Park, Dong Sup Yoon Surgery Today.2021; 51(11): 1775. CrossRef
What do surgeons need to know about the mesopancreas Eduardo de Souza M. Fernandes, Oliver Strobel, Camila Girão, Jose Maria A. Moraes-Junior, Orlando Jorge M. Torres Langenbeck's Archives of Surgery.2021; 406(8): 2621. CrossRef
Room for improvement in the treatment of pancreatic cancer: Novel opportunities from gene targeted therapy Michail Galanopoulos, Aris Doukatas, Filippos Gkeros, Nikos Viazis, Christos Liatsos World Journal of Gastroenterology.2021; 27(24): 3568. CrossRef
Guidelines for the diagnosis and treatment of pancreatic cancer in China (2021) Yinmo Yang, Xueli Bai, Dapeng Bian, Shouwang Cai, Rufu Chen, Feng Cao, Menghua Dai, Chihua Fang, Deliang Fu, Chunlin Ge, Xiaochao Guo, Chunyi Hao, Jihui Hao, Heguang Huang, Zhixiang Jian, Gang Jin, Fei Li, Haimin Li, Shengping Li, Weiqin Li, Yixiong Li, H Journal of Pancreatology.2021; 4(2): 49. CrossRef
Paraaortic dissection in “total mesopancreas excision” and “mesopancreas-first resection” pancreaticoduodenectomies for pancreatic cancer: Useless, optional, or necessary?A systematic review Nadia Peparini Surgical Oncology.2021; 38: 101639. CrossRef
Impact of molecular surgical margin analysis on the prediction of pancreatic cancer recurrences after pancreaticoduodenectomy Yuki Sunagawa, Masamichi Hayashi, Suguru Yamada, Hiroshi Tanabe, Keisuke Kurimoto, Nobutake Tanaka, Fuminori Sonohara, Yoshikuni Inokawa, Hideki Takami, Mitsuro Kanda, Chie Tanaka, Goro Nakayama, Masahiko Koike, Yasuhiro Kodera Clinical Epigenetics.2021;[Epub] CrossRef
Development and External Validation of Survival Prediction Model for Pancreatic Cancer Using Two Nationwide Databases: Surveillance, Epidemiology and End Results (SEER) and Korea Tumor Registry System-Biliary Pancreas (KOTUS-BP) Jae Seung Kang, Lydia Mok, Jin Seok Heo, In Woong Han, Sang Hyun Shin, Yoo-Seok Yoon, Ho-Seong Han, Dae Wook Hwang, Jae Hoon Lee, Woo Jung Lee, Sang Jae Park, Joon Seong Park, Yonghoon Kim, Huisong Lee, Young-Dong Yu, Jae Do Yang, Seung Eun Lee, Il Young Gut and Liver.2021; 15(6): 912. CrossRef
Recurrence patterns of pancreatic cancer after pancreatoduodenectomy: systematic review and a single-centre retrospective study Marit Kalisvaart, Damian Broadhurst, Francesca Marcon, Rupaly Pande, Andrea Schlegel, Robert Sutcliffe, Ravi Marudanayagam, Darius Mirza, Nikolaos Chatzizacharias, Manuel Abradelo, Paolo Muiesan, John Isaac, Yuk T. Ma, Christopher McConville, Keith Robert HPB.2020; 22(9): 1240. CrossRef
Positive neck margin at frozen section analysis is a significant predictor of tumour recurrence and poor survival after pancreatodudenectomy for pancreatic cancer Stefano Crippa, Giovanni Guarneri, Giulio Belfiori, Stefano Partelli, Michele Pagnanelli, Giulia Gasparini, Gianpaolo Balzano, Marco Schiavo Lena, Corrado Rubini, Claudio Doglioni, Giuseppe Zamboni, Massimo Falconi European Journal of Surgical Oncology.2020; 46(8): 1524. CrossRef
Resection or repair of large peripancreatic arteries during robotic pancreatectomy Emanuele F. Kauffmann, Niccolò Napoli, Concetta Cacace, Francesca Menonna, Fabio Vistoli, Gabriella Amorese, Ugo Boggi Updates in Surgery.2020; 72(1): 145. CrossRef
In the Era of the Leeds Protocol: A Systematic Review and A Meta-Analysis on the Effect of Resection Margins on Survival Among Pancreatic Ductal Adenocarcinoma Patients B. Kurlinkus, R. Ahola, E. Zwart, A. Halimi, B. S. Yilmaz, G. O. Ceyhan, J. Laukkarinen Scandinavian Journal of Surgery.2020; 109(1): 11. CrossRef
Systematic Analysis of Accuracy in Predicting Complete Oncological Resection in Pancreatic Cancer Patients—Proposal of a New Simplified Borderline Resectability Definition Louisa Bolm, Katharina Mueller, Katharina May, Stefan Sondermann, Ekaterina Petrova, Hryhoriy Lapshyn, Kim Christin Honselmann, Dirk Bausch, Sergii Zemskov, Peter Bronsert, Tobias Keck, Steffen Deichmann, Ulrich F. Wellner Cancers.2020; 12(4): 882. CrossRef
Survival of pancreatic cancer patients is negatively correlated with age at diagnosis: a population-based retrospective study Hongcheng Wang, Jiazhe Liu, Guanggai Xia, Shizhou Lei, Xiuyan Huang, Xinyu Huang Scientific Reports.2020;[Epub] CrossRef
Circumferential resection margin (CRM) in pancreatic cancer Lena Häberle, Irene Esposito Surgery in Practice and Science.2020; 1: 100006. CrossRef
Clinical impacts of resection margin status and clinicopathologic parameters on pancreatic ductal adenocarcinoma Tsengelmaa Jamiyan, Takayuki Shiraki, Yoshihiro Kurata, Masanori Ichinose, Keiichi Kubota, Yasuo Imai World Journal of Surgical Oncology.2020;[Epub] CrossRef
Prognostic Implications of 18-FDG Positron Emission Tomography/Computed Tomography in Resectable Pancreatic Cancer Cosimo Sperti, Alberto Friziero, Simone Serafini, Sergio Bissoli, Alberto Ponzoni, Andrea Grego, Emanuele Grego, Lucia Moletta Journal of Clinical Medicine.2020; 9(7): 2169. CrossRef
Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma Aaron J. Grossberg, Linda C. Chu, Christopher R. Deig, Eliot K. Fishman, William L. Hwang, Anirban Maitra, Daniel L. Marks, Arnav Mehta, Nima Nabavizadeh, Diane M. Simeone, Colin D. Weekes, Charles R. Thomas CA: A Cancer Journal for Clinicians.2020; 70(5): 375. CrossRef
Survival benefit of adjuvant chemoradiotherapy for positive or close resection margin after curative resection of pancreatic adenocarcinoma Byoung Hyuck Kim, Kyubo Kim, Jin-Young Jang, Wooil Kwon, Hongbeom Kim, Kyung-Hun Lee, Do-Youn Oh, Haeryoung Kim, Kyung Bun Lee, Eui Kyu Chie European Journal of Surgical Oncology.2020; 46(11): 2122. CrossRef
Pre‐operative diabetes mellitus does not worsen survival and post‐operative outcomes in Chinese patients undergoing resection for pancreatic adenocarcinoma Adrian H. K. Yu, Albert C. Y. Chan Surgical Practice.2020; 24(4): 132. CrossRef
Multiagent neoadjuvant chemotherapy and tumor response are associated with improved survival in pancreatic cancer Nathan M. Bolton, Adam H. Maerz, Russell E. Brown, Mona Bansal, John S. Bolton, William C. Conway HPB.2019; 21(4): 413. CrossRef
The learning curve for a surgeon in robot-assisted laparoscopic pancreaticoduodenectomy: a retrospective study in a high-volume pancreatic center Tao Zhang, Zhi-Ming Zhao, Yuan-Xing Gao, Wan Yee Lau, Rong Liu Surgical Endoscopy.2019; 33(9): 2927. CrossRef
Selecting chemotherapy for pancreatic cancer: Far away or so close? Si Shi, Xianjun Yu Seminars in Oncology.2019; 46(1): 39. CrossRef
Adjuvant chemotherapy followed by concurrent chemoradiation is associated with improved survival for resected stage I‐II pancreatic cancer Sung Jun Ma, Gregory M. Hermann, Kavitha M. Prezzano, Lucas M. Serra, Austin J. Iovoli, Anurag K. Singh Cancer Medicine.2019; 8(3): 939. CrossRef
Duktales Adenokarzinom des Pankreas E. Gallmeier, T. M. Gress Der Gastroenterologe.2019; 14(2): 131. CrossRef
Management of pancreatic head adenocarcinoma: From where to where? Kemal Dolay, Fatma Umit Malya, Sami Akbulut World Journal of Gastrointestinal Surgery.2019; 11(3): 143. CrossRef
Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma Vincent P. Groot, Georgios Gemenetzis, Alex B. Blair, Roberto J. Rivero-Soto, Jun Yu, Ammar A. Javed, Richard A. Burkhart, Inne H. M. Borel Rinkes, I. Quintus Molenaar, John L. Cameron, Matthew J. Weiss, Christopher L. Wolfgang, Jin He Annals of Surgery.2019; 269(6): 1154. CrossRef
A Prospective Clinical Trial to Determine the Effect of Intraoperative Ultrasound on Surgical Strategy and Resection Outcome in Patients with Pancreatic Cancer Babs G. Sibinga Mulder, Shirin Feshtali, Arantza Fariña Sarasqueta, Alexander L. Vahrmeijer, Rutger-Jan Swijnenburg, Bert A. Bonsing, J. Sven D. Mieog Ultrasound in Medicine & Biology.2019; 45(8): 2019. CrossRef
Microvascular invasion is a major prognostic factor after pancreatico‐duodenectomy for adenocarcinoma Fabrizio Panaro, Tarek Kellil, Julie Vendrell, Valentina Sega, Regis Souche, Tullio Piardi, Piera Leon, Christophe Cassinotto, Eric Assenat, Edoardo Rosso, Francis Navarro Journal of Surgical Oncology.2019; 120(3): 483. CrossRef
Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer Yoonhyeong Byun, Youngmin Han, Jae Seung Kang, Yoo Jin Choi, Hongbeom Kim, Wooil Kwon, Sun‐Whe Kim, Do‐Youn Oh, Sang Hyub Lee, Ji Kon Ryu, Yong‐Tae Kim, Jin‐Young Jang Journal of Hepato-Biliary-Pancreatic Sciences.2019; 26(9): 416. CrossRef
Keratin 17 identifies the most lethal molecular subtype of pancreatic cancer Lucia Roa-Peña, Cindy V. Leiton, Sruthi Babu, Chun-Hao Pan, Elizabeth A. Vanner, Ali Akalin, Jela Bandovic, Richard A. Moffitt, Kenneth R. Shroyer, Luisa F. Escobar-Hoyos Scientific Reports.2019;[Epub] CrossRef
Comment on “The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma” Niccolo Petrucciani, Laura Antolino, Giovanni Moschetta, Giovanni Ramacciato Annals of Surgery.2019; 270(6): e129. CrossRef
Determining Optimal Routes to Surgery for Borderline Resectable Venous Pancreatic Cancer—Where Is the Least Harm and Most Benefit? Rupaly Pandé, Keith J. Roberts Frontiers in Oncology.2019;[Epub] CrossRef
Duktales Adenokarzinom des Pankreas E. Gallmeier, T. M. Gress Der Internist.2018; 59(8): 805. CrossRef
Adjuvant Chemotherapy Versus Chemoradiation for Patients with Resected Pancreatic Adenocarcinoma: A Single-Center Retrospective Study Do Young Kim, Young Jin Choi, Young Mi Seol, Hyojeong Kim The Korean Journal of Pancreas and Biliary Tract.2018; 23(3): 108. CrossRef
Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes Andrew McGuigan, Paul Kelly, Richard C Turkington, Claire Jones, Helen G Coleman, R Stephen McCain World Journal of Gastroenterology.2018; 24(43): 4846. CrossRef
The TRIANGLE operation – radical surgery after neoadjuvant treatment for advanced pancreatic cancer: a single arm observational study Thilo Hackert, Oliver Strobel, Christoph W. Michalski, André L. Mihaljevic, Arianeb Mehrabi, Beat Müller-Stich, Christoph Berchtold, Alexis Ulrich, Markus W. Büchler HPB.2017; 19(11): 1001. CrossRef
Purpose
This study was conducted to evaluate the long-term outcome in patients undergoing pancreaticoduodenectomy (PD) followed by adjuvant chemoradiotherapy for distal cholangiocarcinoma (DCC) in a high-volume center and to identify the prognostic impact of clinicopathologic factors.
Materials and Methods
A total of 132 consecutive patients who met the inclusion criteria were retrieved from the institutional database from January 1995 to September 2009. All patients received adjuvant treatments at a median of 45 days after the surgery. Median follow-up duration was 57 months (range, 6 to 225 months) for all patients and 105 months for survivors (range, 13 to 225 months).
Results
The 5-year locoregional recurrence-free survival (LRRFS), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS) rates were 70.7%, 55.7%, 49.4%, and 48.1%, respectively. Univariate analysis revealed poorly differentiated (P/D) tumors and lymph node (LN) metastasis were significantly associated with DMFS and OS. Additionally, preoperative carbohydrate antigen 19-9 level was significantly correlated with DFS, LRRFS, and DMFS. Upon multivariate analysis for OS, P/D tumors (p=0.015) and LN metastasis (p=0.003) were significant prognosticators that predicted inferior OS. Grade 3 or higher late gastrointestinal toxicity occurred in only one patient (0.8%).
Conclusion
Adjuvant chemoradiotherapy after PD for DCC is an effective and tolerable strategy without significant side effects. During long-term follow-up, we found that prognosis of DCC was mainly influenced by histologic differentiation and LN metastasis. For patients with these risk factors, further research should focus on improving adjuvant strategies as well as other treatment approaches.
Citations
Citations to this article as recorded by
Patterns, timing and predictors of recurrence following pancreaticoduodenectomy for distal cholangiocarcinoma: An international multicentre retrospective cohort study Peter LZ. Labib, Thomas B. Russell, Jemimah L. Denson, Mark A. Puckett, Fabio Ausania, Elizabeth Pando, Keith J. Roberts, Ambareen Kausar, Vasileios K. Mavroeidis, Ricky H. Bhogal, Gabriele Marangoni, Sarah C. Thomasset, Adam E. Frampton, Duncan R. Spaldi European Journal of Surgical Oncology.2024; 50(6): 108353. CrossRef
Liver Transplantation for Cholangiocarcinoma Nadine Soliman, Ashton A. Connor, Sudha Kodali, Rafik Mark Ghobrial Digestive Disease Interventions.2024; 08(04): 239. CrossRef
Durable Response to Pembrolizumab and Lenvatinib in a Patient with Chemotherapy-refractory Cholangiocarcinoma Winn Soe P, Huang Yiwu Archives of Cancer Science and Therapy.2024; 8(1): 041. CrossRef
Impact of adjuvant therapy on outcomes after curative‐intent resection for distal cholangiocarcinoma Jing‐Jing Hou, Shishir K. Maithel, Sharon M. Weber, George Poultsides, Christopher L. Wolfgang, Ryan C. Fields, Jin He, Charles Scoggins, Kamron Idrees, Perry Shen, Xu‐Feng Zhang, Timothy M. Pawlik Journal of Surgical Oncology.2023; 127(4): 607. CrossRef
The short- and long-term outcomes of pancreaticoduodenectomy for distal cholangiocarcinoma Pavel Skalicky, Ondrej Urban, Jiri Ehrmann, Hana Svebisova, Dusan Klos, Jana Tesarikova, Cestmir Neoral, Katerina Knapkova, Martin Lovecek Biomedical Papers.2022; 166(4): 386. CrossRef
Patterns of Regional Failure after Pancreaticoduodenectomy in Patients with Distal Extrahepatic Cholangiocarcinoma: Suggestion of the Clinical Target Volume for Elective Nodal Irradiation W. Jung, Y. Park, K. Kim, H.J. Park, B.H. Kim Clinical Oncology.2022; 34(1): e45. CrossRef
Pathological, molecular, and clinical characteristics of cholangiocarcinoma: A comprehensive review Mukul Vij, Yogesh Puri, Ashwin Rammohan, Gowripriya G, Rajesh Rajalingam, Ilankumaran Kaliamoorthy, Mohamed Rela World Journal of Gastrointestinal Oncology.2022; 14(3): 607. CrossRef
The prognostic value of the lymph node ratio in patients with distal cholangiocarcinoma after curative intended surgery: A single-center retrospective study Chaeyung Oh, Hee Joon Kim, Sang Hwa Song, Eun Kyu Park, Young Hoe Hur, Yang Seok Koh, Chol Kyoon Cho Annals of Hepato-Biliary-Pancreatic Surgery.2022; 26(2): 168. CrossRef
Etiology, Clinical Presentations, and Short-Term Treatment Outcomes of Extrahepatic Obstructive Jaundice in South-Western Uganda Charles Newton Odongo, Carlos Cabrera Dreque, David Mutiibwa, Felix Bongomin, Felix Oyania, Mvuyo Maqhawe Sikhondze, Moses Acan, Raymond Atwine, Fred Kirya, Martin Situma Clinical and Experimental Gastroenterology.2022; Volume 15: 79. CrossRef
Lymph Node Ratio Nomogram-Based Prognostic Model for Resected Distal Cholangiocarcinoma Marc Perez, Carsten Palnaes Hansen, Fernando Burdio, Gianluca Pellino, Adolfo Pisanu, Roberto Salvia, Marcello Di Martino, Mohammad Abu Hilal, Luca Aldrighetti, Benedetto Ielpo Journal of the American College of Surgeons.2022; 235(5): 703. CrossRef
Surgical management of biliary malignancy T. Peter Kingham, Victoria G. Aveson, Alice C. Wei, Jason A. Castellanos, Peter J. Allen, Daniel P. Nussbaum, Yinin Hu, Michael I. D'Angelica Current Problems in Surgery.2021; 58(2): 100854. CrossRef
Survival benefit with adjuvant radiotherapy after resection of distal cholangiocarcinoma: A propensity‐matched National Cancer Database analysis Sivesh K. Kamarajah, Filip Bednar, Clifford S. Cho, Hari Nathan Cancer.2021; 127(8): 1266. CrossRef
Re-appraising the role of lymph node status in predicting survival in resected distal cholangiocarcinoma – A meta-analysis and systematic review Ken Min Chin, Marcello Di Martino, Nicholas Syn, Benedetto Ielpo, Mohammad Abu Hilal, Brian K.P. Goh, Ye Xin Koh, Mikel Prieto European Journal of Surgical Oncology.2021; 47(6): 1267. CrossRef
The Role of Adjuvant Chemoradiotherapy in Nonhilar Extrahepatic Bile Duct Cancer: A Long-Term Single-Institution Analysis Won Ick Chang, Byoung Hyuck Kim, Hyun-Cheol Kang, Kyubo Kim, Kyung-Hun Lee, Do-Youn Oh, Hongbeom Kim, Wooil Kwon, Jin-Young Jang, Eui Kyu Chie International Journal of Radiation Oncology*Biology*Physics.2021; 111(2): 395. CrossRef
Differences in Prognostic Factors and Recurrence Patterns After Curative-Intent Resection of Perihilar and Distal Cholangiocarcinomas V. Sallinen, J. Sirén, H. Mäkisalo, T. E. Lehtimäki, E. Lantto, A. Kokkola, A. Nordin Scandinavian Journal of Surgery.2020; 109(3): 219. CrossRef
Prognostic factors and patterns of recurrence after curative resection for patients with distal cholangiocarcinoma Weiwen Zhou, Liwen Qian, Yi Rong, Qiong Zhou, Jingjing Shan, Ping Li, Liming Shi, Hai Liu, Xiaonan Sun Radiotherapy and Oncology.2020; 147: 111. CrossRef
Proposed Modification of Staging for Distal Cholangiocarcinoma Based on the Lymph Node Ratio Using Korean Multicenter Database Yunghun You, Yong Chan Shin, Dong Wook Choi, Jin Seok Heo, Sang Hyun Shin, Naru Kim, Kee-Taek Jang, Hongbeom Kim, Chang-Sup Lim, Sun Hee Chang, Kang Min Han, In Woong Han Cancers.2020; 12(3): 762. CrossRef
Combined treatment options for resectable common bile duct cancer patients A. N. Polyakov, D. V. Podluzhny, Y. I. Patyutko, S. V. Chulkova, A. V. Egorova, I. S. Bazin, M. A. Shorikov, D. Yu. Frantsev, A. Yu. Syskova Annaly khirurgicheskoy gepatologii = Annals of HPB Surgery.2020; 25(3): 123. CrossRef
The Evolving Role of Radiation Therapy in the Treatment of Biliary Tract Cancer Eleni Gkika, Maria A. Hawkins, Anca-Ligia Grosu, Thomas B. Brunner Frontiers in Oncology.2020;[Epub] CrossRef
Prognostic Significance of the Lymph Node Ratio in Surgical Patients With Distal Cholangiocarcinoma Xiaocheng Li, Huapeng Lin, Yu Sun, Jianping Gong, Huyi Feng, Jingkai Tu Journal of Surgical Research.2019; 236: 2. CrossRef
PROGNOSTIC FACTORS FOR RESECTABLE COMMON BILE DUCT CANCER A. Yu. Syskova, I. S. Stilidi, A. N. Polyakov Research'n Practical Medicine Journal.2019; 6(2): 69. CrossRef
Association of Preoperative Platelet-to-Lymphocyte Ratio with Poor Outcome in Patients with Distal Cholangiocarcinoma Sojun Hoshimoto, Shoichi Hishinuma, Hirofumi Shirakawa, Moriaki Tomikawa, Iwao Ozawa, Yoshiro Ogata Oncology.2019; 96(6): 290. CrossRef
Patterns of failure after resection of extrahepatic bile duct cancer: implications for adjuvant radiotherapy indication and treatment volumes Hoon Sik Choi, Ki Mun Kang, Bae Kwon Jeong, Hojin Jeong, Yun Hee Lee, In Bong Ha, Tae Gyu Kim, Jin Ho Song Radiation Oncology.2018;[Epub] CrossRef
Impact of adjuvant chemotherapy after pancreaticoduodenectomy for distal cholangiocarcinoma: a propensity score analysis from a French multicentric cohort Damien Bergeat, Olivier Turrini, Laetitia Courtin-Tanguy, Stéphanie Truant, Benjamin Darnis, Jean Robert Delpero, Jean-Yves Mabrut, Nicolas Regenet, Laurent Sulpice Langenbeck's Archives of Surgery.2018; 403(6): 701. CrossRef
Purpose The purpose of this study is to compare the prognostic efficacy of the number and location of positive lymph nodes (LN), LN ratio (LNR), and log odds of positive LNs (LODDs) in highrisk cervical cancer treated with radical surgery and adjuvant treatment. Materials and Methods Fifty high-risk patients who underwent radical hysterectomy and pelvic node dissection followed by adjuvant treatment were analyzed retrospectively. The patients had International Federation of Gynecology and Obstetrics (FIGO) stage IA2-IIB. Upper LN is defined as common iliac or higher LN, and LNR is the ratio of positive LNs to harvested LNs. LODDs is log odds between positive LNs and negative LNs. Radiotherapy was delivered to the whole pelvis with median 50.4 Gy/28 Fx± to the para-aortic regions. Platinum-based chemotherapy was used in most patients (93%). The median follow-up duration was 80 months. Results The 5-year disease-free survival (DFS) rate was 76.1%, and the overall survival (OS) rate was 86.4%. Treatment failure occurred in 11 patients, and distant failure (DF) was the dominant pattern (90.9%). In univariate analysis, significantly lower DFSwas observed in patients with perineural invasion, ≥ 2 LN metastases, LNR ≥ 10%, upper LN metastasis, and ≥ –1.05 LODDs. In multivariate analysis, ≥ –1.05 LODDs was the only significant factor for DFS (p=0.011). Of patients with LODDs ≥ –1.05, 40.9% experienced DF. LODDs was the only significant prognostic factor for OS as well (p=0.006). Conclusion LODDs ≥ –1.05 was the only significant prognostic factor for both DFS and OS. In patients with LODDs ≥ –1.05, intensified chemotherapy might be required, considering the high rate of DF.
Citations
Citations to this article as recorded by
Perineural invasion in cervical cancer: A multicenter retrospective study Xiaolin Chen, Hui Duan, Hongwei Zhao, Fangjie He, Lu Yin, Yueping Liu, Lixia Wang, Chunlin Chen European Journal of Surgical Oncology.2024; 50(6): 108313. CrossRef
Recent Advances in Cervical Cancer Management: A Review on Novel Prognostic Factors in Primary and Recurrent Tumors Angela Santoro, Frediano Inzani, Giuseppe Angelico, Damiano Arciuolo, Emma Bragantini, Antonio Travaglino, Michele Valente, Nicoletta D’Alessandris, Giulia Scaglione, Stefania Sfregola, Alessia Piermattei, Federica Cianfrini, Paola Roberti, Gian Franco Za Cancers.2023; 15(4): 1137. CrossRef
Development and Validation of Novel Nomograms to Predict the Overall Survival and Cancer-Specific Survival of Cervical Cancer Patients With Lymph Node Metastasis Jianying Yi, Zhili Liu, Lu Wang, Xingxin Zhang, Lili Pi, Chunlei Zhou, Hong Mu Frontiers in Oncology.2022;[Epub] CrossRef
Treatment Strategies and Prognostic Factors of 2018 FIGO Stage IIIC Cervical Cancer: A Review Fengying Qin, Huiting Pang, Tao Yu, Yahong Luo, Yue Dong Technology in Cancer Research & Treatment.2022;[Epub] CrossRef
The Log Odds of Positive Lymph Nodes Predict Survival of Advanced-Stage Endometrial Cancer: A Retrospective Analysis of 3230 Patients in the Surveillance, Epidemiology, and End Results Database Christopher G. Smith, Quan Chen, Bin Huang, Rachel W. Miller, Christopher P. DeSimone, Charles S. Dietrich, Frederick R. Ueland, Holly H. Gallion, Edward J. Pavlik, John R. van Nagell, Lauren A. Baldwin Branch Journal of Gynecologic Surgery.2022; 38(4): 278. CrossRef
The extent of aortic lymphadenectomy in locally advanced cervical cancer impacts on survival Antoni Llueca, Javier Escrig, Antonio Gil-Moreno, Virginia Benito, Alicia Hernández, Berta Díaz-Feijoo Journal of Gynecologic Oncology.2021;[Epub] CrossRef
Lymph Node Ratio Is a Strong Prognostic Factor in Patients with Early-Stage Cervical Cancer Undergoing Minimally Invasive Radical Hysterectomy Se Ik Kim, Tae Hun Kim, Maria Lee, Hee Seung Kim, Hyun Hoon Chung, Taek Sang Lee, Hye Won Jeon, Jae-Weon Kim, Noh Hyun Park, Yong-Sang Song Yonsei Medical Journal.2021; 62(3): 231. CrossRef
The role of lymph nodes in cervical cancer: incidence and identification of lymph node metastases—a literature review Ester P. Olthof, Maaike A. van der Aa, Judit A. Adam, Lukas J. A. Stalpers, Hans H. B. Wenzel, Jacobus van der Velden, Constantijne H. Mom International Journal of Clinical Oncology.2021; 26(9): 1600. CrossRef
Prognostic implications of ENE and LODDS in relation to lymph node-positive colorectal cancer location Tengfei Li, Yan Yang, Weidong Wu, Zhongmao Fu, Feichi Cheng, Jiahui Qiu, Qi Li, Kundong Zhang, Zai Luo, Zhengjun Qiu, Chen Huang Translational Oncology.2021; 14(11): 101190. CrossRef
The prognostic value of lymph node ratio in stage IIIC cervical cancer patients triaged to primary treatment by radical hysterectomy with systematic pelvic and para-aortic lymphadenectomy Koray Aslan, Mehmet Mutlu Meydanli, Murat Oz, Yusuf Aytac Tohma, Ali Haberal, Ali Ayhan Journal of Gynecologic Oncology.2020;[Epub] CrossRef
Radiomic signature as a predictive factor for lymph node metastasis in early‐stage cervical cancer Yangyang Kan, Di Dong, Yuchen Zhang, Wenyan Jiang, Nannan Zhao, Lu Han, Mengjie Fang, Yali Zang, Chaoen Hu, Jie Tian, Chunming Li, Yahong Luo Journal of Magnetic Resonance Imaging.2019; 49(1): 304. CrossRef
The Prognostic Impact of the Number of Metastatic Lymph Nodes and a New Prognostic Scoring System for Recurrence in Early-Stage Cervical Cancer with High Risk Factors: A Multicenter Cohort Study (KROG 15-04) Jeanny Kwon, Keun-Young Eom, Young Seok Kim, Won Park, Mison Chun, Jihae Lee, Yong Bae Kim, Won Sup Yoon, Jin Hee Kim, Jin Hwa Choi, Sei Kyung Chang, Bae Kwon Jeong, Seok Ho Lee, Jihye Cha Cancer Research and Treatment.2018; 50(3): 964. CrossRef
Log odds of positive lymph nodes may predict survival benefit in patients with node-positive non-small cell lung cancer Weiye Deng, Ting Xu, Yifan Wang, Yujin Xu, Pei Yang, Daniel Gomez, Zhongxing Liao Lung Cancer.2018; 122: 60. CrossRef
Prognostic significance of lymph node ratio in node-positive cervical cancer patients Ji Hyeon Joo, Young Seok Kim, Joo-Hyun Nam Medicine.2018; 97(30): e11711. CrossRef
Prognostic Value of Fluorine-18 Fluorodeoxyglucose Uptake of Bone Marrow on Positron Emission Tomography/Computed Tomography for Prediction of Disease Progression in Cervical Cancer Jeong Won Lee, Seob Jeon, Seong Taek Mun, Sang Mi Lee International Journal of Gynecological Cancer.2017; 27(4): 776. CrossRef
Tosol Yu, Keun-Yong Eom, Na Young Jang, Kyung Su Kim, Tae Ryool Koo, Jeanny Kwon, Byoung Hyuck Kim, Eunyoung Kang, Sung-Won Kim, Jae-Sung Kim, In Ah Kim
Cancer Res Treat. 2016;48(2):491-498. Published online June 22, 2015
Purpose The purpose of this study is to evaluate objective cosmetic outcomes and factors related to breast-conserving therapy (BCT) using the BCCT.core software.
Materials and Methods Fifty-one patients who received BCT with informed consent were evaluated using the BCCT.core software. Patients were divided into two groups based on the BCCT score: excellent or good (n=42) vs. fair or poor (n=9). Analysis of clinical factors was performed to determine factors affecting cosmetic outcomes.
Results The objective cosmetic outcome of BCT measured using the BCCT.core software was excellent in 10% of patients, good in 72%, and fair in 18%. None of the patients were classified as poor outcome. Tumor characteristics, systemic adjuvant therapy (chemotherapy and hormonal therapy), and radiation dose or energy of electron boost did not show correlation with the score measured by the BCCT.core program (p > 0.05). In univariate analysis, maximum dose within the breast (Dmax), width of tangential field, and excised tumor volume were smaller in patients with excellent or good by the BCCT.core compared to those with fair or poor (Dmax, 110.2±1.5% vs. 111.6±1.7%, p=0.019; width of tangential field, 8.0±1.1 cm vs. 8.6±0.7 cm, p=0.034; excised tumor volume, 64.0±35.8 cm3 vs. 95.3±54.4 cm3, p=0.067). In multivariate analysis, only Dmax was a significant factor for breast cosmetic outcome with a risk ratio of 1.697 (95% confidence interval, 1.006 to 2.863; p=0.047).
Conclusion Objective measurement of cosmetic outcome of BCT using the BCCT.core software was feasible. The cosmetic outcome of BCT may be affected by the maximum dose within the breast.
Citations
Citations to this article as recorded by
Impact of autologous breast reconstruction on bra fit Yen-Tung Liu, Novera H. Khan, Mary Catherine Bordes, Gregory P. Reece, Ashleigh M. Francis, Tzuan A. Chen, Karen Bravo, Mia K. Markey Supportive Care in Cancer.2024;[Epub] CrossRef
Easy Anthropometric Measurements Are Representative of Baseline Values of Breast Q Values in Asymptomatic Women Giuseppe Catanuto, Nicola Rocco, Concetta G. Fichera, Ada Cinquerrui, Martina Rapisarda, Paolo Chiodini, Francesca Magnoni, Patrizia Dorangricchia, Valeria Sebri, Gabriella Pravettoni, Maurizio Bruno Nava, Francesco Caruso Healthcare.2024; 12(2): 268. CrossRef
Outcomes of reconstructive techniques in breast cancer using BCCT. core software Sevgi Kurt, Ahmet Serkan İlgün, Enver Özkurt, Gürsel Soybir, Gül Alço, Çağlar Ünal, Filiz Elbüken Çelebi, Tomris Duymaz, Tuğba Kayan Tapan, Naziye Ak, Çetin Ordu, Vahit Özmen World Journal of Surgical Oncology.2024;[Epub] CrossRef
Evaluating intra and inter-observer bias in the cosmetic rating for random vs. serial assessment of breast photographs Preeti Belani, Rima Pathak, Shraddha Kenekar, Gaurika Pokale, Pallavi Rane, Ashwini Chalke, Tabassum Wadasadawala The Royal College of Radiologists Open.2024; 2: 100152. CrossRef
Comparison of Postoperative Breast Asymmetry Using Vectra 3D Imaging in Prepectoral Versus Subpectoral Implant-Based Breast Reconstruction Seung-Ho Choi, Sang-Oh Lee, Kyu-Jin Chung, Il-Kug Kim, Jun-Ho Lee Journal of Clinical Medicine.2024; 13(23): 7486. CrossRef
Long-term Efficacy and Cosmetic Outcomes of Partial-breast Irradiation Using Multicatheter Interstitial Brachytherapy for Breast-conserving Therapy Kazuhiko SATO, Hiromi FUCHIKAMI, Naoko TAKEDA, Nana NATSUME, Masahiro KATO Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association).2023; 84(2): 238. CrossRef
Identification of key breast features using a neural network: applications of machine learning in the clinical setting of Plastic Surgery Nitzan Kenig, Javier Monton Echeverria, Luis De la Ossa Plastic & Reconstructive Surgery.2023;[Epub] CrossRef
Breast cancer patient-reported outcome of factors influencing cosmetic satisfaction after breast-conserving therapy A. T. P. M. Brands-Appeldoorn, A. J. G. Maaskant-Braat, L. Janssen, L. A. D. M. van Osch, V. C. G. Tjan-Heijnen, R. M. H. Roumen Breast Cancer.2022; 29(1): 114. CrossRef
BROWSE: A multicentre comparison of nine year outcomes in acellular dermal matrix based and complete submuscular implant-based immediate breast reconstruction-aesthetics, capsular contracture and patient reported outcomes Rebecca L. Wilson, Cliona C. Kirwan, Joe M. O'Donoghue, Richard A. Linforth, Richard K. Johnson, James R. Harvey European Journal of Surgical Oncology.2022; 48(1): 73. CrossRef
Factors related to patient-reported cosmetic outcome after breast-conserving therapy for breast cancer A. T. P. M. Brands-Appeldoorn, R. C. M. Thomma, L. Janssen, A. J. G. Maaskant-Braat, V. C. G. Tjan-Heijnen, R. M. H. Roumen Breast Cancer Research and Treatment.2022; 191(3): 545. CrossRef
Adaptation of BCCT Learning Model in Developing Religious Aspects of Children Abd Hamid Wahid, Muhammad Fajri, Hasan Baharun, Riana Imroatul Fitriyah, Arifatur Risqiyah Jurnal Obsesi : Jurnal Pendidikan Anak Usia Dini.2022; 6(4): 3439. CrossRef
Methods of Esthetic Assessment after Adjuvant Whole-Breast Radiotherapy in Breast Cancer Patients: Evaluation of the BCCT.core Software and Patients’ and Physicians’ Assessment from the Randomized IMRT-MC2 Trial Tobias Forster, Clara Köhler, Melissa Dorn, Matthias Felix Häfner, Nathalie Arians, Laila König, Semi Ben Harrabi, Ingmar Schlampp, Eva Meixner, Vanessa Heinrich, Nicola Weidner, Michael Golatta, André Hennigs, Jörg Heil, Holger Hof, David Krug, Jürgen De Cancers.2022; 14(12): 3010. CrossRef
Feasibility of anomaly score detected with deep learning in irradiated breast cancer patients with reconstruction Dong-Yun Kim, Soo Jin Lee, Eun-Kyu Kim, Eunyoung Kang, Chan Yeong Heo, Jae Hoon Jeong, Yujin Myung, In Ah Kim, Bum-Sup Jang npj Digital Medicine.2022;[Epub] CrossRef
Breast Oncoplastic Resections: No Innovation Without Evaluation Sherif Monib, Mohamed Farag, Mohamed Ibrahim Indian Journal of Surgery.2021; 83(S2): 409. CrossRef
Cosmetic Outcomes of a Phase 1 Dose Escalation Study of 5-Fraction Stereotactic Partial Breast Irradiation for Early Stage Breast Cancer Asal Rahimi, Howard E. Morgan, Dong W. Kim, Yuanyuan Zhang, Marilyn Leitch, Rachel Wooldridge, Sally Goudreau, Barbara Haley, Roshni Rao, Aeisha Rivers, Ann E. Spangler, Ryan T. Jones, Stella Stevenson, Jason Staley, Kevin Albuquerque, Chul Ahn, Sarah Neu International Journal of Radiation Oncology*Biology*Physics.2021; 110(3): 772. CrossRef
Comparative study between laparoscopically harvested omental flap and glandular flap in immediate reconstruction after conservative surgery in breast cancer Waleed Y. El‐Sherpiny, Abdulhamid M. Abdelshafi, Mohamed Ghazaly, Ayman A. Elnemr, Ahmed A. Darwish, Mohamed A. Mlees Surgical Practice.2021; 25(2): 92. CrossRef
Reliability of the BCCT.core software in evaluation of breast cosmesis – A systematic review Stami Trakis, Heidi Lord, Peter Graham, Ritin Fernandez Journal of Medical Imaging and Radiation Oncology.2021; 65(6): 817. CrossRef
New criteria for breast symmetry evaluation after breast conserving surgery for cancer RENÉ ALOISIO DA COSTA VIEIRA, GABRIELE BILLER, FABIOLA CRISTINA BRANDINI DA SILVA, JONATHAS JOSÉ DA SILVA, MARCO ANTÔNIO DE OLIVEIRA, ANTÔNIO BAILÃO-JUNIOR Revista do Colégio Brasileiro de Cirurgiões.2021;[Epub] CrossRef
Use of Symmetry Assessment Methods in the Context of Breast Surgery Javier Monton, Asia Torres, Maria Gijon, Luis Chang-Azancot, Nitzan Kenig, P. Camelia Trandafir, Joaquin Jordan, Ricardo Insausti Aesthetic Plastic Surgery.2020; 44(5): 1440. CrossRef
Visual Breast Asymmetry Assessment with Optical-Flow Algorithm Javier Monton, Nitzan Kenig, Ricardo Insausti, Joaquin Jordan Journal of Medical Systems.2020;[Epub] CrossRef
Nueva metodología para medir simetría frontal en pacientes reconstruidas por cáncer de mama Lenia Sánchez Wals, Carlos Acosta-Batista, Oscar Luis Vera Pérez, Juan Jesús Lence Anta, Marco Marcasciano Revista de Senología y Patología Mamaria.2019; 32(4): 133. CrossRef
Objective assessment of flap volume changes and aesthetic results after adjuvant radiation therapy in patients undergoing immediate autologous breast reconstruction Yujin Myung, Yousung Son, Tae-hyun Nam, Eunyoung Kang, Eun-Kyu Kim, In Ah Kim, Keun-Yong Eom, Chan Yeong Heo, Jae Hoon Jeong, Fabio Santanelli, di Pompeo d'Illasi PLOS ONE.2018; 13(5): e0197615. CrossRef